Vijay Modur

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Childhood Cancer

Quality Control

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana
A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer. Cancer research communications 3 (6) (2023)
Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana
A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer. Cancer research communications 3 (6) (2023)
Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana
A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer. Cancer research communications 3 (6) (2023)
Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana
A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer. Cancer research communications 3 (6) (2023)
Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana
A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer. Cancer research communications 3 (6) (2023)